Opendata, web and dolomites

MAP-Detector

Development of a novel low dose, high resolution, high contrast X-ray detector for medical applications to improve patient diagnoses and reduce the risk of X-radiation induced cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAP-Detector project word cloud

Explore the words cloud of the MAP-Detector project. It provides you a very rough idea of what is the project "MAP-Detector" about.

dose    patented    rapid    material    plate    thoroughly    whilst    earlier    certification    former    clinical    latter    showing    inspection    2011    gt    business    reduce    medical    cadmium    imaging    dosage    accounting    2012    technique    cdte    cancer    4bn    plan    segment    share    47    requirement    1bn    ray    exposes    diagnostic    detector    significantly    drafting    materials    segments    mammography       ibex    culminate    telluride    map    solutions    accounted    grow    radiation       route    disruptive    countries    market    patients    leverage    13    initial    27    retrofitted    global    conduct    valuable    detection    21    preparation    plus    superior    trials    industry    compatible    innovative    ct    0bn    incorporating    keenly    introduction    exposure    50    absorption    2017    treatment    seeking    detectors       risk    surpasses    fluoroscopy    intend    manufacturers    discrimination    offers    enhanced   

Project "MAP-Detector" data sheet

The following table provides information about the project.

Coordinator
IBEX INNOVATIONS LTD 

Organization address
address: DISCOVERY 2 NETPARK
city: SEDGEFIELD
postcode: TS21 3FH
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.ibexinnovations.co.uk
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBEX INNOVATIONS LTD UK (SEDGEFIELD) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

X-ray imaging is a valuable medical diagnostic technique, accounting for 47% of the medical imaging market in 2011. However, current X-ray detection technology exposes patients to increased risk of developing cancer with research in 13 developing countries showing that exposure to X-ray detection technology accounted for 0•6% to 1•8% of the cancer cases. X-ray detector manufacturers are thus keenly seeking technology that would reduce radiation exposure (dose) to patients whilst offering superior material discrimination for earlier detection and treatment of clinical cases. As IBEX, we have developed and patented an innovative X-ray detection technology incorporating our unique Multi Absorption Plate (MAP). Our technology significantly surpasses current solutions based on cadmium telluride (CdTe) as it offers potential dose reduction of >50% plus enhanced materials discrimination. MAP-Detector offers a disruptive X-ray detector that will leverage the MAP technology in both retrofitted and new build X-ray detectors for medical applications. The global medical diagnostic imaging market is expected to grow from €21.4bn in 2012 to €27.4bn by 2017, with X-ray and CT imaging equipment having a 50%/€13.1bn share in 2017. Within this segment, the X-ray imaging detector market is estimated at €2.0bn. Our technology will be compatible with the leading X-ray inspection systems creating significant market potential. Our initial target segments within the medical industry are fluoroscopy and mammography with dosage reduction being far more important for the former and materials discrimination an essential requirement for the latter. In Phase 1 we will thoroughly analyse the market to more clearly define our route to market and requirements for rapid market uptake. This will culminate in the drafting of a more detailed operational business plan. In Phase 2 we intend to conduct clinical trials and achieve certification for our technology in preparation for market introduction.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAP-DETECTOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAP-DETECTOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More